HK1201281A1 - Canine/feline cd20 binding epitope and compositions for binding thereto - Google Patents

Canine/feline cd20 binding epitope and compositions for binding thereto Download PDF

Info

Publication number
HK1201281A1
HK1201281A1 HK15101787.8A HK15101787A HK1201281A1 HK 1201281 A1 HK1201281 A1 HK 1201281A1 HK 15101787 A HK15101787 A HK 15101787A HK 1201281 A1 HK1201281 A1 HK 1201281A1
Authority
HK
Hong Kong
Prior art keywords
amino acid
binding
acid sequence
present
contiguous amino
Prior art date
Application number
HK15101787.8A
Other languages
English (en)
Chinese (zh)
Inventor
Gearing David
Original Assignee
Nexvet Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexvet Australia Pty Ltd filed Critical Nexvet Australia Pty Ltd
Publication of HK1201281A1 publication Critical patent/HK1201281A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
HK15101787.8A 2011-10-13 2012-10-12 Canine/feline cd20 binding epitope and compositions for binding thereto HK1201281A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546865P 2011-10-13 2011-10-13
US201161546865P 2011-10-13
PCT/GB2012/052532 WO2013054127A1 (en) 2011-10-13 2012-10-12 Canine/feline cd20 binding epitope and compositions for binding thereto

Publications (1)

Publication Number Publication Date
HK1201281A1 true HK1201281A1 (en) 2015-08-28

Family

ID=47023030

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101787.8A HK1201281A1 (en) 2011-10-13 2012-10-12 Canine/feline cd20 binding epitope and compositions for binding thereto

Country Status (7)

Country Link
US (1) US20140294819A1 (https=)
EP (1) EP2766391A1 (https=)
JP (1) JP2015501146A (https=)
AU (1) AU2012322445B2 (https=)
CA (1) CA2851758A1 (https=)
HK (1) HK1201281A1 (https=)
WO (1) WO2013054127A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6701079B2 (ja) * 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． ヒトｐｄ−１に対するイヌ化マウス抗体
NZ744192A (en) * 2016-02-18 2019-11-29 Elanco Us Inc Chimeric canine anti-cd20 antibody
US11673961B2 (en) 2018-02-20 2023-06-13 Memorial Sloan Kettering Cancer Center Anti-CD20 antibody and uses thereof
CA3145347A1 (en) * 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
CA3147809A1 (en) * 2019-08-29 2021-03-04 Shyr Jiann Li Anti-il31 antibodies for veterinary use
JP2021059499A (ja) 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
EP4355782A1 (en) * 2021-06-17 2024-04-24 Petmedix Ltd. Anti canine cd20 antibodies
EP4602073A2 (en) * 2022-11-15 2025-08-20 Purdue Research Foundation Canine pd-l1 antibody, antigen binding fragments thereof, and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485126A4 (en) * 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
JP4263951B2 (ja) * 2003-06-20 2009-05-13 財団法人日本生物科学研究所 イヌ化抗体の作成方法および使用
EP1751187A2 (en) * 2004-05-28 2007-02-14 Idexx Laboratories, Inc. Canine cd20 compositions
CA2711882C (en) * 2008-01-11 2016-07-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Improved humanized anti-human .alpha.9-integrin antibody
EP2725037A1 (en) * 2008-09-04 2014-04-30 Vet Therapeutics, Inc. Monoclonal antibodies binding canine CD20
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
WO2011057188A1 (en) * 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies

Also Published As

Publication number Publication date
US20140294819A1 (en) 2014-10-02
EP2766391A1 (en) 2014-08-20
AU2012322445A1 (en) 2014-04-24
WO2013054127A1 (en) 2013-04-18
NZ623644A (en) 2015-03-27
AU2012322445B2 (en) 2016-12-15
CA2851758A1 (en) 2013-04-18
JP2015501146A (ja) 2015-01-15

Similar Documents

Publication Publication Date Title
HK1201281A1 (en) Canine/feline cd20 binding epitope and compositions for binding thereto
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
UA117901C2 (uk) Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
PH12014500380A1 (en) Modified proteins and peptides
SG194707A1 (en) Amino acid sequence presenting fusion polypeptide and its use
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NZ601591A (en) Methods for treating pancreatic cancer
PE20120415A1 (es) Anticuerpos anti-igf
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
MY183134A (en) Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
PE20140133A1 (es) Nuevas proteinas de union a antigenos
EP2403871A4 (en) FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES
WO2012046061A3 (en) Clostridium difficile antigens
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
MY173334A (en) Antibodies that bind to tl1a and their uses
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
WO2010142551A3 (en) Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
MY166152A (en) Anti-human xcr1 antibodies
EA201270701A1 (ru) Ингибирующие металлопротеины антитела
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
GB201108296D0 (en) Antibodies against tropomyosin-related kinase b receptors